Arcus Biosciences, Inc. (RCUS) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Arcus Biosciences, Inc. (RCUS) trades at a price-to-earnings ratio of -6.2x, with a stock price of $20.37 and trailing twelve-month earnings per share of $-3.29.
The current P/E is 112% below its 5-year average of 52.9x. Over the past five years, RCUS's P/E has ranged from a low of 25.9x to a high of 94.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, RCUS trades at a 126% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, RCUS trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RCUS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Oncology Therapeutics Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
INCYIncyte Corporation | $20B | 15.8 | - | +4173%Best |
GMABGenmab A/S | $18B | 15.4 | 0.53 | +84% |
EXELExelixis, Inc. | $12B | 15.8 | 0.31Best | +58% |
INBXInhibrx Biosciences, Inc. | $1B | 0.6Lowest | - | +2377% |
BBOTBridgeBio Oncology Therapeutics Inc. | $794M | 21.8 | - | - |
PBYIPuma Biotechnology, Inc. | $287M | 9.3 | - | -2% |
CHRSCoherus Oncology, Inc. | $194M | 6.7 | - | +110% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $26.16 | $1.01 | 25.9x | -51% |
| FY2022 Q2 | $25.34 | $0.74 | 34.2x | -35% | |
| FY2022 Q1 | $31.56 | $0.55 | 57.4x | +8% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $40.47 | $0.43 | 94.1x | +78% |
Average P/E for displayed period: 52.9x
See RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RCUS vs AGIO
See how RCUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RCUS stock overvalued or undervalued?
RCUS trades at -6.2x P/E, below its 5-year average of 52.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RCUS's valuation compare to peers?
Arcus Biosciences, Inc. P/E of -6.2x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is RCUS's PEG ratio?
RCUS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.